Plain-English translation of NCT05394714 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I clinical trial testing a new treatment called Magicell-NK for people with early-stage colon cancer who have already had surgery to remove their tumor. The treatment uses your own immune cells (called NK cells), which are grown and activated in the laboratory and then infused back into your body. Researchers want to find the safest and most effective dose of this medication.
Early-stage colon cancer can sometimes return even after successful surgery. This trial is exploring whether giving patients immune cells designed to fight cancer cells might help prevent recurrence and improve long-term outcomes.
You likely qualify if…
You likely don't qualify if…
You will receive six infusions of the immune cell treatment over a period of time at the study site in Taiwan. The trial will monitor your safety closely with blood tests and clinical visits to watch for any side effects. Your doctor will also check how well you are recovering and whether the treatment is helping to prevent cancer recurrence.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Taiwan